Developing the next generation of therapies for immune-mediated disease
PT-002 is a first-in-class small molecule drug which targets epigenetic enzymes involved in allergy.
Allergic disease is caused by hyperreactivity of the immune system to environmental allergens. These hyperreactions are caused by IgE antibodies.
Unlike existing allergy therapies, PT-002 acts to reprogram the immune response to allergens to reduce IgE production. This causes allergen tolerance leading to long-term symptomatic relief.
Pleros Therapeutics is a biotechnology company founded in 2022 by researchers at Virginia Commonwealth University. Our focus is developing small molecule therapies that alter dendritic cell function for the treatment of immunological disorders.
Need more details? Contact us
We are here to assist. Contact us by phone, email or via our social media channels.